1809106217
Base by Base

Advertise on podcast: Base by Base

Rating
★★★☆☆
3
from
2 reviews
This podcast has
477 episodes
Language
English
Publisher
Gustavo Barra
Explicit
No
Date created
2025/04/17
Latest episode
2026/11/12
Average duration
18 min.
Release period
4 days

Description

Base by Base explores advances in genetics and genomics, with a focus on gene-disease associations, variant interpretation, protein structure, and insights from exome and genome sequencing. Each episode breaks down key studies and their clinical relevance—one base at a time. Powered by AI, Base by Base offers a new way to learn on the go. Special thanks to authors who publish under CC BY 4.0, making open-access science faster to share and easier to explore.

Unlock Base by Base podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Base by Base podcast


476: One recurring ABI2 change and a thin brain bridge
2026/11/12
Argilli E et al., The American Journal of Human Genetics - This research letter describes nine unrelated individuals with rare heterozygous missense variants in ABI2, a gene for a cytoskeletal adaptor protein that works in Rac-WAVE signaling and actin remodeling. Seven of them carry the same de novo change, p.Tyr491Cys, in the SH3 domain, and their brain MRIs show a consistent pattern led by a thin corpus callosum, the bundle of fibers that links the two brain hemispheres. Key terms: ABI2, corpus callosum hypoplasia, de novo variant, neurodevelopmental disorder, Rac-WAVE signaling. Study Highlights: Individuals were found through exome or genome sequencing and international data sharing via GeneMatcher, with clinical data from medical records and clinician questionnaires and centrally reviewed brain MRIs. Seven individuals carried the recurrent p.Tyr491Cys variant and two carried distinct de novo variants, p.Val204Met and p.Val463Ala; all variants were absent from gnomAD v4.1. All nine had moderate-to-severe developmental delay and/or intellectual disability, epilepsy occurred in six, and macrocephaly ranging from +2.5 to +4.2 SD was seen in seven of eight individuals. Every individual with p.Tyr491Cys showed marked corpus callosum hypoplasia and periventricular T2-FLAIR hyperintensities, while the two individuals with nonrecurrent variants lacked corpus callosum abnormalities. Conclusion: The authors establish ABI2 as a neurodevelopmental disorder-associated gene and identify the recurrent p.Tyr491Cys variant as defining a distinctive syndrome with corpus callosum hypoplasia and white matter abnormalities, consistent with other Rac-WAVE pathway disorders and with Abi2-deficient mice. The cohort is small, nine individuals, and the mechanism is inferred from structural modeling and prediction tools; the authors state that future functional studies will be needed to explain how the variants cause disease. Article title: Recurrent de novo ABI2 p.Tyr491Cys variants define a neurodevelopmental syndrome with corpus callosum hypoplasia and white matter abnormalities First author: Argilli E Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.10.003 Reference: Argilli E., Yang C., Le C., Retallack H., Elashoff A.M., Parks K., et al. Recurrent de novo ABI2 p.Tyr491Cys variants define a neurodevelopmental syndrome with corpus callosum hypoplasia and white matter abnormalities. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.10.003 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/abi2-tyr491cys-corpus-callosum-neurodevelopmental-syndrome QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 81 - supported by the article: 80 - flagged and reviewed by a human: 1 - metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - A consistent mark on the brain(00:01:08) - Intro and fact-check note(00:01:29) - Study background and ABI2's biology(00:03:22) - Building the cohort(00:04:35) - Locating the recurrent variant(00:05:13) - Clinical features of affected individuals(00:05:49) - Brain MRI findings and the contrast cases(00:07:41) - What it all means and pathway links(00:08:25) - Limitations of the study(00:09:01) - Conclusions and outro
475: A Cell Line Fitness Score Predicts Cancer Risk in Li-Fraumeni Syndrome
2026/11/05
Penkert J et al., The American Journal of Human Genetics - Carriers of disease-causing TP53 variants range from mild to severe cancer phenotypes. Using relative fitness scores from a deep CRISPR mutagenesis screen of 9,225 TP53 mutations, this registry study of 437 individuals from 168 families shows that variants scoring 0.673 or higher go with earlier cancer and with full Li-Fraumeni syndrome. Key terms: Li-Fraumeni syndrome, TP53, deep CRISPR mutagenesis, relative fitness score, cancer surveillance. Study Highlights: A previous screen introduced 9,225 TP53 mutations into a colorectal cancer cell line and scored how well each mutant survived TP53 activators, giving a relative fitness score (RFS). The authors linked these scores to 437 individuals from 168 families in the German Cancer Predisposition Syndrome Registry. Carriers of variants with an RFS of 0.673 or higher developed cancer earlier; an RFS below 0.673 had a hazard ratio of 0.41 (95% CI 0.25 to 0.66, p 0.0002) for cancer. The association held among the 407 individuals whose variant is predicted to produce an altered protein, excluding NULL variants (hazard ratio 0.43). Families with a high score met the definition of Li-Fraumeni syndrome in 110 of 148 cases (74.3%), against 3 of 20 (15%) with a low score. Conclusion: Relative fitness scores from deep CRISPR mutagenesis separated TP53 variant carriers with earlier cancer and more severe Li-Fraumeni spectrum phenotypes, which suggests they could feed future variant classification and tailored surveillance. The finding was not validated in an independent cohort, the scores come from a single colorectal cell line, and they exist only for variants in the DNA binding domain. Article title: Deep CRISPR mutagenesis predicts cancer risk in Li-Fraumeni syndrome First author: Penkert J Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.09.016 Reference: Penkert J., Großhennig A., Dutzmann C.M., Ewert A., Zimmer R., Schoene-Bake J., et al. Deep CRISPR mutagenesis predicts cancer risk in Li-Fraumeni syndrome. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.09.016 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/crispr-fitness-score-cancer-risk-li-fraumeni QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 88 - supported by the article: 87 - flagged and reviewed by a human: 1 - metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - Introduction: TP53 Variants and Li Fraumeni Syndrome(00:01:09) - About This Podcast(00:01:31) - Study Background and Authors(00:02:00) - TP53 Gene Function and Disease Spectrum(00:02:34) - Classifying Full vs Attenuated Li Fraumeni Syndrome(00:03:09) - Measuring Variant Disruption via Deep CRISPR Mutagenesis(00:04:49) - Patient Cohort and Fitness Score Analysis(00:05:30) - Survival Differences by Score Cutoff(00:06:28) - Testing Robustness: Excluding Null Variants(00:07:03) - Family-Level Severity Predictions(00:08:15) - Study Limitations(00:08:47) - Conclusions and Future Implications(00:09:24) - Closing and Credits
474: Two collagen genes, two different risks
2026/11/04
Tzoumkas K et al., The American Journal of Human Genetics - COL4A3 and COL4A4 are paralogous genes that build the same collagen IV network in the kidney filter, and variant guidelines have generally treated them as interchangeable. This episode follows a population-scale study in the UK Biobank, replicated in All of Us, showing that truncating and NC1 domain missense variants carry much stronger associations with hematuria and proteinuria in COL4A4 than in COL4A3, while glycine substitutions behave alike in both genes. Key terms: COL4A3, COL4A4, Alport syndrome, hematuria, UK Biobank. Study Highlights: Using whole-genome sequencing from the UK Biobank (n ≈ 500,000) with replication in All of Us (n ≈ 414,000), the authors ran per-variant association tests, gene-based collapsing analyses and phenome-wide association studies across hematuria, proteinuria and chronic kidney disease. They identified 64 COL4A3 and 92 COL4A4 rare variants significantly associated with hematuria or proteinuria. Glycine substitutions in the collagenous domain conferred similar risks in both genes, but truncating and NC1 missense variants were strongly associated with disease only in COL4A4, with proteinuria case rates of 52.7% and 37.2% in COL4A4 compared with 17.1% and 12.1% in COL4A3. The difference persisted after excluding the British founder variant p.Ser969Ter and was independently replicated in All of Us. A genome-wide analysis found the COL4A3 and COL4A4 locus to be the dominant genetic signal for hematuria, accounted for by rare coding variants, with no evidence of independent trans-acting modifiers. Conclusion: The authors conclude that gene identity, not variant class alone, should inform risk stratification, variant interpretation and genetic counseling in collagen IV heterozygotes. The analyses were restricted to individuals of European ancestry, phenotypes came from ICD-10 codes and laboratory data that likely underestimate prevalence, the difference was not extended to severe CKD, and the mechanism behind the gene-specific effect remains speculative. Article title: Population-scale genomics reveals divergent pathogenicity of variant classes across paralogous collagen IV genes First author: Tzoumkas K Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.10.002 Reference: Tzoumkas K., Doctor G.T., Sadeghi-Alavijeh O., Gale D.P. Population-scale genomics reveals divergent pathogenicity of variant classes across paralogous collagen IV genes. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.10.002 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/col4a3-col4a4-divergent-pathogenicity QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 175 - supported by the article: 174 - flagged and reviewed by a human: 1 - metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - Introduction: Two Collagen Genes, One Question(00:00:39) - About Base by Base(00:01:00) - Type 4 Collagen Genes and Alport Syndrome(00:02:50) - Forms of Alport Syndrome and Heterozygote Risk(00:04:07) - Protein Structure and Variant Classes(00:05:03) - Testing the Paralogue Assumption at Population Scale(00:06:02) - Study Data: UK Biobank and Phenotype Definitions(00:07:16) - Three Levels of Analysis Design(00:09:05) - Single Variant Results for Hematuria and Proteinuria(00:10:29) - Gene Divergence Emerges: Truncating Variants(00:11:37) - Testing the Founder Variant's Influence(00:12:20) - NC1 Missense Variants Confirm the Pattern(00:13:03) - Formal Comparison of Effect Sizes(00:13:47) - Replication in All of Us Cohort(00:14:31) - Genome-Wide Scan Findings(00:15:17) - Interpreting the Genome-Wide Signal(00:15:53) - Clinical Implications for Genetic Counseling(00:16:34) - Why Might the Chains Differ?(00:17:14) - Study Limitations(00:17:54) - Summary and Closing Thoughts(00:19:06) - Credits and Sign-off
473: Sixty years of cells that stop dividing
2026/11/03
Klaver M et al., The EMBO Journal - In 1961, Hayflick and Moorhead showed that normal human fibroblasts divide only a finite number of times. This episode follows a review of the six decades since, as senescence moved from a cell-culture limit to a tumor-suppressive stress response, a tissue-remodeling program, a contributor to aging and disease, and a target for therapy. Key terms: cellular senescence, SASP, senolytics, senomorphics, aging. Study Highlights: This review traces cellular senescence from the Hayflick limit of 1961 through telomere shortening, biomarkers and oncogene-induced senescence. The senescence-associated secretory phenotype revealed that senescent cells actively communicate with their tissues, and later work showed there is no single universal SASP. Genetic ablation in mice showed that senescent cells can contribute causally to age-related decline, while other studies showed roles in wound healing, development and tissue repair, and one p16-lineage study reported detrimental effects on the liver. Senolytics such as dasatinib plus quercetin and senomorphics followed, but UBX0101 failed to show significant benefit in Phase 2 and UBX1325 missed its Phase 2b primary endpoint. The authors identify the lack of validated biomarkers of target engagement as the major bottleneck in clinical senotherapy. Conclusion: The authors conclude that senescence is neither inherently beneficial nor inherently detrimental, and that its consequences depend on context, which senescent cells are involved, and how long they persist. This is a narrative review, not a new experiment, and much of the causal evidence comes from mouse models, with human trials so far early, limited by size or design, or unsuccessful. Article title: Cellular senescence: six decades of discovery and reinvention First author: Klaver M Journal: The EMBO Journal DOI: 10.1038/s44318-026-00922-w Reference: Klaver M., Steeneken L.S., Veeningen N., Altulea A., Demaria M. Cellular senescence: six decades of discovery and reinvention. The EMBO Journal, 45, 7307-7325. (2026). https://doi.org/10.1038/s44318-026-00922-w License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cellular-senescence-six-decades-review QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 183 - supported by the article: 182 - flagged and reviewed by a human: 1 - metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - Introduction: The Hayflick Discovery(00:00:44) - About This Episode and Paper(00:02:30) - Telomere Shortening as a Mechanism(00:03:11) - Finding Markers for Senescence in Tissue(00:03:58) - Oncogene-Induced Senescence and Tumor Suppression(00:04:41) - Multiplying Triggers of Senescence(00:05:29) - Discovery of the SASP Secretory Phenotype(00:06:18) - Complexity and Diversity of SASP Programs(00:07:08) - Testing Causality: Senescent Cell Clearance Models(00:08:25) - Beneficial Roles in Healing and Repair(00:09:00) - Developmental Senescence Discovery(00:10:12) - Senescence and the Aging Hallmarks Framework(00:10:51) - The Persistence Paradox and Disease Links(00:11:37) - Immune Clearance of Senescent Cells(00:12:37) - Immune Evasion and Immunosenescence(00:13:08) - Senolytics: Targeting Senescent Cells(00:13:59) - Senomorphics: Suppressing the SASP(00:14:47) - Early Human Clinical Trials(00:15:32) - Clinical Setbacks and Failures(00:16:16) - The Biomarker Bottleneck(00:17:04) - Toward Precision Senescence Targeting(00:17:51) - Conclusion: Context-Dependent Senescence(00:18:28) - Future Directions and Closing Thoughts
472: 490,319 genomes that fill the gaps in genetic studies
2026/11/02
Wienbrandt L et al., Nature Genetics - Most genetic studies read only a fraction of the genome and infer the rest from a reference panel. This episode covers a new panel built from whole-genome sequencing of 490,319 UK Biobank participants, benchmarked against the TOPMed r3 panel across 35 datasets and used to reanalyze COVID-19 association studies from four European countries. Key terms: genotype imputation, haplotype reference panel, UK Biobank, EagleImp, COVID-19 GWAS. Study Highlights: Researchers phased whole-genome data from 490,319 UK Biobank participants into reference panels of more than 361 million variants and extended EagleImp to run on a standalone server and inside the UK Biobank Research Analysis Platform. Compared with the TOPMed r3 panel of 133,597 individuals, the UK Biobank panel achieved lower phasing switch error rates for all superpopulations except AMR and for 25 of 26 1000 Genomes subpopulations. Mean absolute error improved for 4 of 5 superpopulations and 12 subpopulations, while TOPMed performed better across all frequency categories in AFR. Estimated R2 improved across all 5 superpopulations and 22 subpopulations for variants down to 0.01% frequency, with the largest gain, +24.39%, in East Asian samples. Reimputing an Italian severe COVID-19 study of 835 cases and 1,255 controls yielded a genome-wide significant association at 3p21.31 and a new lead SNP, rs73064425, that matched three independent studies. Conclusion: The authors conclude that the UK Biobank panel is the most suitable panel for imputing worldwide populations when no population-specific panel is available, and that common-variant imputation is not yet saturated in the European populations tested. The benchmark has limits: estimated imputation R2 stays low for most subpopulations below 0.01% frequency, truth-based measures may be inaccurate at low frequencies, and TOPMed r3 still performed better in AFR on mean absolute error and holds more panel-specific variants. Article title: A haplotype reference panel constructed from 490,319 UK Biobank genomes improves genotype imputation for global populations First author: Wienbrandt L Journal: Nature Genetics DOI: 10.1038/s41588-026-02819-0 Reference: Wienbrandt L., Prieß C., Schmöhl M., Neff V., Gretsova M., Torres G., et al. A haplotype reference panel constructed from 490,319 UK Biobank genomes improves genotype imputation for global populations. Nature Genetics. (2026). https://doi.org/10.1038/s41588-026-02819-0 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/uk-biobank-haplotype-reference-panel-imputation QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 176 - supported by the article: 143 - flagged and reviewed by a human: 33 - metadata checks passed: 4 of 4 QC result: Warn. Chapters (00:00:03) - The Restorer Analogy: Imputation Explained(00:01:03) - Genotyping Chips and the Need for Imputation(00:02:16) - Introducing the Study and Its Authors(00:02:55) - What Haplotypes Are and How Imputation Works(00:03:44) - Limits of Existing Panels: Access and Scale(00:04:37) - Is Imputation Already Saturated?(00:05:20) - Building the UK Biobank Panel(00:06:38) - Creating the Lighter Panel and Software Tools(00:07:11) - Designing the Benchmark(00:08:39) - Phasing Results: UK Biobank vs TopMed(00:09:49) - Checking Against Known Truth: Mixed Results(00:10:38) - Testing on Real GWAS Datasets(00:11:14) - Speed and Efficiency Gains(00:11:52) - The Italian COVID-19 Case Study(00:13:12) - Fine-Mapping the Causal Variant(00:13:53) - Revisiting the Saturation Question(00:14:58) - Limitations of the Study(00:15:35) - Remaining Gaps and Future Directions(00:16:12) - Conclusion: What the Bigger Archive Reveals
471: How cancer treatment picks winners among mutant clones in the normal esophagus
2026/10/30
Fowler J et al., Nature Genetics - Normal esophageal lining is a patchwork of mutant clones that compete for space as we age. This study asked whether cancer treatment changes which of those clones win. Normal esophagus removed at surgery from 70 patients with esophageal cancer, who had received no treatment, combination chemotherapy (ECX, EOX or FLOT) or chemoradiation (CROSS), was analyzed with duplex (NanoSeq), whole-genome and targeted sequencing, alongside protein structure modeling and a CRISPR experiment in mouse esophageal cultures. Key terms: somatic mutation, clonal selection, esophagus, chemoradiation, TP53. Study Highlights: Targeted sequencing of 1,995 samples of 2 mm2 across 324 cancer-associated genes found 23,692 independent mutations, and no chemotherapy mutational signature was detected, suggesting most clones existed before treatment. In patients given CROSS, the proportion of epithelium mutant for TP53 and PPM1D was double that of the other groups, their mutational burden and deletion burden were higher, and over 5% of samples carried a copy number event covering the TP53 locus. HLA-B and SPOP mutants were selected only in CROSS patients, with 13 of 22 HLA-B nonsynonymous mutations predicted to abolish the protein. RAC1, NFE2L2 and MTOR mutants were under positive selection only in the FLOT group, the only regimen giving 5-fluorouracil together with leucovorin, and structural modeling suggested the MTOR mutants would likely remain sensitive to rapalogs. In mouse esophageal cultures, guide RNAs targeting exon 6 of Ppm1d were enriched after irradiation but not after 5-fluorouracil. Conclusion: Weeks of neoadjuvant treatment can reshape a mutational landscape built over decades, selectively expanding preexisting mutant clones in a treatment-specific way, which may point to genes involved in cellular resilience to therapy. The groups were small (FLOT had seven patients), exposure data were limited, the mouse experiment did not test the full CROSS combination, the selection of MTOR, RAC1 and NFE2L2 mutants by 5-fluorouracil is inferred rather than tested, and selection in normal tissue cannot be assumed to match selection in cancer cells. Article title: Cancer treatment alters mutant selection in normal esophagus First author: Fowler J Journal: Nature Genetics DOI: 10.1038/s41588-026-02738-0 Reference: Fowler J.C., Arbore G., Sood R.K., Abnizova I., Albarello L., Pickering O., et al. Cancer treatment alters mutant selection in normal esophagus. Nature Genetics, 58, 2566-2578. (2026). https://doi.org/10.1038/s41588-026-02738-0 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cancer-treatment-mutant-selection-normal-esophagus QC: This episode's script was checked sentence by sentence against the full text of the original article, by an automated process with human review, before it was recorded. QC Summary: - sentences checked: 171 - supported by the article: 167 - flagged and reviewed by a human: 4 - metadata checks passed: 4 of 4 QC result: Pass. Chapters (00:00:03) - The Forest Fire Analogy: Introduction(00:00:37) - Introducing Base by Base and the Paper(00:00:58) - Mutant Clones in the Aging Esophagus(00:01:29) - The Research Question and Team(00:02:21) - Treatment Regimens: Chemotherapy and CROSS(00:03:04) - The Study Opportunity at Surgery(00:03:44) - Mutational Signatures Explained(00:04:23) - Patient Cohort and Tissue Sampling(00:05:07) - Sequencing Methods: Mapping the Clones(00:06:16) - Measuring Selection in Genes(00:06:49) - Protein Structure Modeling and Lab Tests(00:07:23) - No Treatment-Specific Mutational Signature Found(00:07:50) - CROSS Group Stands Out: Mutation Load(00:09:01) - PPM1D Mutations and Radiation Resistance(00:10:07) - Chromosome 17 and TP53 Disruption in CROSS(00:10:41) - HLA-B and SPOP Selection in CROSS Patients(00:11:15) - FLOT-Selected Genes: NFE2L2, RAC1, MTOR(00:12:25) - RAC1 and MTOR Mechanisms in FLOT(00:13:44) - Interpreting the Findings: Speed of Change(00:14:16) - Why TP53 Results Matter for Cancer Risk(00:14:57) - The FLOT Question: Resistance Implications(00:15:34) - Study Limitations(00:16:12) - Summary: Different Fires, Different Winners(00:16:50) - Closing Thoughts and Credits
470: The hidden swaps CRISPR leaves between sister chromosomes
2026/10/29
Chovanec P et al., eLife - When CRISPR/Cas9 cuts DNA, editing is usually judged by the small insertions and deletions left at the break. But a cut can also be repaired by swapping DNA between the two identical sister chromatids, an exchange that leaves no sequence change and is invisible to standard sequencing. Using sci-L3-Strand-seq, a single-cell method that reads which parental template strand each daughter cell inherited, this study mapped Cas9-induced sister chromatid exchange (SCE) in human cells, after cutting either one unique site or 237 repetitive Alu sites at once. Key terms: CRISPR/Cas9, sister chromatid exchange, Strand-seq, DNA double-strand break repair, structural variants. Study Highlights: Duplex Cas9 cleavage at a single site or at 237 repetitive targets caused a pronounced G1/S arrest within 24 hr, while the D10A and H840A nickases did not measurably perturb cell-cycle progression after washout. Cutting a unique locus strongly enriched SCE at the break site, reaching 41% in the same cell cycle and 17% in the subsequent division. Across all cells, cutting 237 Alu sites gave only mild on-target enrichment, 1.20-fold in the post-washout condition (n=2547 cells), but a high-SCE subset of 261 cells showed 1.39-fold enrichment with an average of 14.61 on-target SCEs per cell. Reciprocal daughter-cell pair analysis found that 14 of 50 Cas9-induced SCE events were coupled with structural variants, in contrast to 87 of 87 spontaneous SCEs in XRCC1-null cells that were reciprocal and copy-neutral in a companion study. Cutting inside LIG3, LIG4, XRCC1 and XRCC4 did not change genome-wide SCE counts, with a median of three SCEs per cell in all four conditions, consistent with delayed functional loss after editing. Conclusion: Cas9-induced double-strand breaks are potent local triggers of sister chromatid exchange, and a measurable fraction of these exchanges carries structural alterations that conventional sequencing cannot see, so they do not universally reflect error-free homologous recombination. All experiments were done in wild-type cells, Cas9 can cut the same site several times so individual outcomes cannot be tied to a single cleavage event, and the deletion signature pointing to a TRAIP/under-replicated-region pathway rests on a single daughter-cell pair. Article title: Genome-wide mapping of Cas9-induced sister chromatid exchange across single and over 200 genomic sites in human cells First author: Chovanec P Journal: eLife DOI: 10.7554/eLife.112073 Reference: Chovanec P., He S., Yin Y. Genome-wide mapping of Cas9-induced sister chromatid exchange across single and over 200 genomic sites in human cells. eLife, 15. (2026). https://doi.org/10.7554/eLife.112073 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cas9-sister-chromatid-exchange-strand-seq QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-29. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/outro, and music - transcript... Chapters (00:00:03) - The Deck of Cards Analogy(00:00:41) - Intro and Fact-Check Note(00:01:02) - Sister Chromatids and Silent Swaps(00:01:33) - Cas9 Scissors and Hidden Repairs(00:02:08) - Paper Introduction(00:02:44) - How Cas9 Cuts Are Normally Repaired(00:03:24) - Bigger Damage Beyond Small Edits(00:03:57) - Defining Sister Chromatid Exchange(00:04:17) - Four Broken Ends and Open Questions(00:05:28) - Strand-Seq: Reading the Backs of the Cards(00:06:37) - Experimental Design and Guides(00:07:46) - Cell Cycle Arrest Findings(00:08:22) - Exchanges Pile Up at the Cut Site(00:08:53) - Interpreting the 41% Exchange Rate(00:10:02) - Checking Repair Gene Targets(00:10:34) - Cutting 237 Sites at Once(00:11:11) - High-Exchange Cell Subsets(00:12:22) - Reciprocal Daughter Pairs and Clean Trades(00:12:53) - When Trades Aren't Clean(00:13:24) - Rethinking How We Judge Edits(00:14:00) - Isochromatid Breaks and Mechanism(00:14:59) - Caveats on Causation and Single Observations(00:15:55) - Conclusions and Implications(00:16:51) - Closing and Credits
469: What the shape of a face reveals about cleft risk
2026/10/27
Herrick N et al., Human Genetics and Genomics Advances - Orofacial clefts are among the most common birth defects, affecting about 1 in 700 births, yet known genetic signals explain only a fraction of their heritability, and cleft studies cannot reach the huge sample sizes used for traits like height. This study borrowed statistical power from a related trait: the genetics of normal human face shape. Using a pleiotropy-informed method called conditional false discovery rate, the team re-analyzed an existing GWAS of nonsyndromic cleft lip with or without cleft palate and found new candidate risk loci, three of which passed a 5% FDR threshold in an independent replication cohort. Key terms: orofacial cleft, facial shape, GWAS, conditional false discovery rate, pleiotropy. Study Highlights: The team conditioned summary statistics from a European nsCL/P GWAS of 3,969 individuals on two independent facial shape GWASs, from 4,680 US and 3,566 UK individuals. SNPs associated with nsCL/P were enriched among SNPs associated with facial shape but not among those for unrelated traits such as height, schizophrenia or LDL cholesterol. The cFDR approach identified 21 independent loci at a 5% threshold and 15 more at 10%, and the new loci had effect sizes comparable to known ones, with no significant difference in a Mann-Whitney U test (p = 0.26). Of 13 new lead SNPs tested in The Cleft Collective cohort of 1,084 affected individuals and 7,913 controls, five replicated at p 0.05, and loci near MSX2, ASPSCR1 and FHOD3 passed a 5% FDR threshold. Spatial transcriptomics of a Carnegie stage 13 human embryo showed expression and gene specificity scores for these genes in the pharyngeal arches, among other regions. Conclusion: Leveraging the shared genetics of face shape and clefting can recover cleft risk loci that a standard GWAS of the same data misses, and it supports the long-standing idea that embryonic face shape is itself part of cleft risk. The analysis is limited to people of European ancestry, the authors expect about 10% of the 36 loci to be false positives, not every new locus replicated, and the expression data support but do not prove a role for the candidate genes. Article title: Leveraging the genetics of human face shape boosts the discovery of orofacial cleft risk loci First author: Herrick N Journal: Human Genetics and Genomics Advances DOI: 10.1016/j.xhgg.2026.100655 Reference: Herrick N., Goovaerts S., Manchel A., Lee M.K., Zhang X., Davies A., et al. Leveraging the genetics of human face shape boosts the discovery of orofacial cleft risk loci. Human Genetics and Genomics Advances, 7, 100655. (2026). https://doi.org/10.1016/j.xhgg.2026.100655 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/face-shape-genetics-orofacial-cleft-risk-loci QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-27. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/outro, and music - transcript coverage: All scientific... Chapters (00:00:03) - Introduction: Face Shape and Clefts(00:01:21) - The Study and Researchers(00:02:18) - Background on Orofacial Clefts(00:03:28) - The Face-Cleft Genetic Link Hypothesis(00:04:46) - The CFDR Method Explained(00:05:21) - Study Data and Controls(00:07:01) - Analysis Details and Validation Approach(00:07:41) - Results: Face Shape as a Predictive Map(00:08:17) - Main Findings: New Cleft Loci Discovered(00:08:49) - Comparing US and UK Cohorts(00:09:23) - Are New Loci Real? Effect Size Check(00:09:56) - Replication in the Cleft Collective Cohort(00:11:06) - Regional Plots of Three Candidate Genes(00:11:36) - Gene Expression in the Embryo(00:12:41) - Spatial Genetic Risk Mapping (GSMap)(00:13:17) - MSX2: A Known Suspect Confirmed(00:13:53) - ASPSCR1 and FHOD3: New Biological Clues(00:15:05) - Bigger Picture: Shared Genetic Architecture(00:16:10) - Limitations of the Study(00:16:48) - Conclusions and Closing Thoughts
468: When a splicing factor breaks in different ways
2026/10/25
Lisfeld J et al., The American Journal of Human Genetics - SRSF3 is an essential splicing factor, one of the serine/arginine-rich proteins that help cells cut and paste their RNA messages and send them out of the nucleus. Losing it completely is lethal in mouse embryos. This study describes nine individuals with new, non-inherited SRSF3 variants and variable developmental phenotypes, with developmental delay and/or mild to moderate intellectual disability as the most consistent feature. Functional experiments in patient fibroblasts and human cell lines showed that each variant damaged the protein in a different combination of ways, which may help explain why affected individuals differ so much. Key terms: SRSF3, splicing, de novo variants, neurodevelopmental disorder, spliceosomopathy. Study Highlights: Through GeneMatcher, the team recruited nine subjects with six heterozygous de novo SRSF3 variants: two missense variants in the RNA recognition motif, three frameshifts and a recurrent nonsense variant, p.Arg149*, found in four unrelated subjects. In fibroblasts from subject 3, transcripts carrying the c.330_331del frameshift were largely degraded by nonsense-mediated decay, with only about 12.5% of SRSF3 reads carrying the deletion, yet overall SRSF3 mRNA and protein levels were normal, suggesting compensation from the other allele. In HEK293T cells, all five variant proteins tested formed less complex with polyadenylated RNA than wild type, while the three C-terminally truncated proteins were poorly phosphorylated, less stable, at about 46% to 59% of wild-type levels, and showed reduced nucleocytoplasmic shuttling in HeLa cells. Complex formation with the export factors YTHDC1 and NXF1 was reduced for p.Arg137Ilefs*16 and p.Arg149* and increased for p.Ser81Trp. Conclusion: De novo SRSF3 variants define a new spliceosomopathy with a broad developmental spectrum, and the variants appear to act through distinct mechanisms rather than simple loss of half the protein. The cohort is small, most functional work used overexpressed proteins in cell lines rather than affected tissues, the evidence against haploinsufficiency comes from one subject and one cell type, and the c.330_331del variant remains of uncertain significance. Article title: De novo variants in the essential splicing factor gene SRSF3 cause variable developmental phenotypes First author: Lisfeld J Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.09.018 Reference: Lisfeld J., Chinn I.K., Yuan B., Casar C., Müller C., Elron E., et al. De novo variants in the essential splicing factor gene SRSF3 cause variable developmental phenotypes. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.09.018 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/srsf3-de-novo-variants-splicing-factor-development QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-25. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, in... Chapters (00:00:03) - Introduction: Nine Children, One Gene(00:01:03) - The Film Editor Analogy(00:01:42) - Study Credits and Paper Overview(00:02:23) - Understanding Splicing and the Spliceosome(00:02:57) - SR Proteins and SRSF3 Basics(00:03:29) - SRSF3 Structure and Phosphorylation Cycle(00:04:41) - SRSF3's Self-Regulating Poison Exon(00:05:18) - Finding the Children via GeneMatcher(00:05:55) - Types of Variants Found(00:06:30) - Lab Methods: Testing the Variants(00:07:05) - Control Variants for Validation(00:07:33) - Clinical Features of the Children(00:08:02) - Variability Within the Same Variant(00:08:44) - Subject 3: A Surprising Compensation(00:09:16) - Confirming Normal Protein Levels in Subject 3(00:09:48) - Interpreting Subject 3's Uncertain Variant(00:10:20) - Tail Tagging Experiments(00:11:19) - Protein Stability and Tag Protection(00:11:28) - RNA Gripping Deficits Across Variants(00:11:50) - Nuclear Shuttling Defects(00:12:36) - Export Partner Binding Differences(00:13:06) - Each Variant's Unique Defect Combination(00:13:44) - SRSF3 as a New Spliceosomopathy(00:14:18) - Comparison to SRSF1 and Clinical Implications(00:14:52) - Challenging Assumptions About Truncating Variants(00:15:24) - Study Limitations(00:16:02) - Summary: One Gene, Many Breaks(00:16:35) - Closing and Credits
467: Finding mutations carried by fewer than 1 in 100 cells
2026/10/18
Jang Y et al., The American Journal of Human Genetics - Every cell in the body picks up its own small set of DNA changes over a lifetime, and many of these somatic mutations are carried by only a tiny fraction of cells. This study, part of the SMaHT Network, asks how reliably standard bulk whole-genome sequencing can find mutations present at a variant allele fraction below 1%. The team built a ground truth from one donor's skin: clonal stem cell lines grown from single fibroblasts defined real mutations, and lines from other skin biopsies of the same donor defined mutations that should be absent. With about 1,360× Illumina coverage confirmed by PacBio and AVITI, point mutations below 1% were detected accurately in the easily mapped parts of the genome. Key terms: somatic mosaicism, whole-genome sequencing, variant allele fraction, benchmarking, SMaHT. Study Highlights: Primary fibroblasts from a 29-year-old donor contained five subclones, captured as clonal iPSC lines, giving benchmark mutations from 0.1% to 25% variant allele fraction, while iPSC lines from other biopsies of the same donor supplied negative controls; both sets held about 11,000 SNVs and 2,800 indels. Using the negative controls, PacBio and AVITI had the lowest substitution error rates in easy regions, 0.003% and 0.005%, and mismatch rates rose by 1 to 2 orders of magnitude in harder regions. In fibroblasts, more than 99.5% of bulk-only calls above 1% were confirmed by PacBio or AVITI, the estimated false-positive rate was near zero above 0.8% and about 11% below 0.5%, and homopolymer indels could be detected reliably only above 3%. In postmortem lung and colon, combining about 200× from two tissues found 13 additional shared mutations, a 145% gain in sensitivity below 3%, all confirmed by PacBio or single-cell data. Conclusion: Ultra-deep bulk whole-genome sequencing can detect point mutations below 1% allele fraction with high accuracy, provided calling is restricted to easily mapped regions and sample quality is checked, and pooling coverage across tissues from one donor recovers shared developmental mutations. The benchmark comes from a single donor's fibroblasts, confirmation below 0.5% was limited by long-read and AVITI coverage, most indels sit in homopolymers or hard regions where detection remains unreliable, and postmortem samples needed extra filtering. Article title: Accurate detection of sub-1% frequency somatic mutations by whole-genome sequencing First author: Jang Y Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.09.010 Reference: Jang Y., Gardiner S., Wang Y., Natu A., Dehankar M.K., Tomasini L., et al. Accurate detection of sub-1% frequency somatic mutations by whole-genome sequencing. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.09.010 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/detecting-sub-1-percent-somatic-mutations-wgs QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-18. QC Scope: - article metadata...
466: A quieter MECP2 switch and the male bias in autism
2026/10/16
Meyer-Schuman R et al., The American Journal of Human Genetics - Autism is diagnosed about four times more often in male individuals than in female individuals, and one explanation is mild variants in dosage-sensitive genes on the X chromosome, which a female carrier can buffer with her second copy but a male cannot. This study tests that idea in MECP2, the Rett syndrome gene, by looking at the switches that control how much of it is made rather than the gene itself. Using a massively parallel reporter assay in human stem-cell-derived neurons, the team mapped the active transcription factor binding sites in five MECP2 regulatory elements and tested 22 ultra-rare variants passed from unaffected mothers to autistic sons. Two variants changed regulatory activity, and one in the promoter lowered MECP2 RNA and protein by about 30% when edited into the native gene. Key terms: MECP2, autism, massively parallel reporter assay, noncoding variants, X chromosome. Study Highlights: Whole-genome data from 30,916 individuals in 8,245 autism families yielded 22 ultra-rare noncoding variants in MECP2 regulatory elements, each private to one family, found only in male probands and inherited from an unaffected mother, tested alongside 19 gnomAD control variants. Shuffling predicted transcription factor motifs mapped activator or repressor hotspots in four of the five elements, and knocking down two predicted activators, TCF3 and ZNF281, lowered MECP2 RNA by about 55% and 47% after three weeks. A variant in the primate-specific repressor element CRE A, carried by two affected brothers, increased activity in both the reporter and luciferase assays. The promoter variant g.154097837A>G, found in a boy with autism and ADHD and a full-scale IQ of 97, weakened NFY-B binding at the MECP2 promoter from the 51st to the 9th percentile of bound promoters and reduced MECP2 RNA and protein by about 30% in edited neurons. Conclusion: The findings suggest that noncoding MECP2 variants that modestly lower or raise expression can contribute to idiopathic, male-biased autism, and they provide a framework for finding regulatory variants in other X chromosome neurodevelopmental genes. The evidence rests on two families and on reporter assays and edited neurons in a dish, which take short sequences out of their native chromatin context, so the link between these variants and autism still needs additional variant discoveries and molecular validation. Article title: A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism First author: Meyer-Schuman R Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.09.011 Reference: Meyer-Schuman R., Cherry F., Sui Y., Papastathopoulos-Katsaros A., Zhong Y., Li Y., et al. A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism. The American Journal of Human Genetics. (2026). https://doi.org/10.1016/j.ajhg.2026.09.011 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/mecp2-regulatory-variants-male-biased-autism QC:... Chapters (00:00:20) - Introduction: A Family Mystery(00:01:19) - The X Chromosome and Autism's Male Bias(00:01:45) - The Dimmer Switch Analogy(00:02:35) - Introducing the Study and Authors(00:03:13) - MECP2 Gene and Dose Sensitivity(00:04:27) - Mouse Evidence for Narrow Safe Range(00:05:33) - The Broader X-Linked Puzzle(00:06:10) - Finding Candidate Regulatory Elements(00:06:45) - Selecting Variants from Families(00:07:20) - Massively Parallel Reporter Assay Explained(00:08:30) - Testing in Human Neurons(00:08:56) - Mapping Hotspots Across Elements(00:09:50) - Identifying Transcription Factors(00:10:27) - Switch Teamwork and Context Dependence(00:10:57) - Element A Variant in Two Brothers(00:12:14) - Promoter Variants and Luciferase Testing(00:12:48) - The Boy with the Promoter Variant(00:13:22) - CRISPR Validation of NFY Binding Loss(00:14:18) - Measuring the Downstream Effects(00:14:57) - What the Findings Add Up To(00:15:32) - Why Mild Cases Survive the Filter(00:16:03) - Beyond MECP2: Broader Implications(00:16:33) - Study Limitations(00:17:15) - Conclusion: Quiet Switches and the Future(00:18:13) - Closing and Credits
465: When a lysosomal storage gene shows up only in the retina
2026/10/11
Lin et al., The American Journal of Human Genetics - Bi-allelic variants in IDUA classically cause mucopolysaccharidosis type I, a lysosomal storage disorder that affects many organs from childhood. This study describes 14 adults and young adults from 12 families who first came to eye clinics with retinitis pigmentosa and were later found to carry bi-allelic IDUA variants. Seven of them showed no systemic features of the disease even after detailed assessment, and enzyme activity in white blood cells was reduced but never absent. Cell-based enzyme assays and long-read RNA sequencing explain how mild, hypomorphic alleles can leave just enough enzyme to spare the body but not the retina. Key terms: IDUA, mucopolysaccharidosis type I, retinitis pigmentosa, hypomorphic variants, splicing. Study Highlights: Individuals aged 19 to 73 were recruited from inherited retinal disease cohorts in the UK, Ireland, Italy, the Netherlands and the United States, and none carried two null alleles; most had a loss-of-function allele paired with a missense variant. Leukocyte alpha-L-iduronidase activity was reduced but detectable in all nine individuals tested, and urine glycosaminoglycans were above normal in only half of those tested, with modest elevations. In an IDUA-knockout cell line, several missense variants, including p.His91Tyr and p.Arg383His, showed relative specific activity around 0.5% to 1.5% of wild type, with poor processing or stability. The recurrent c.298A>G variant left enzyme activity intact as a protein change, but nanopore long-read sequencing showed that it mostly causes exon 2 skipping, with only about 1.3% of reads from that allele spliced normally. Conclusion: Hypomorphic IDUA genotypes that leave low residual enzyme activity can cause late-onset retinitis pigmentosa with mild or apparently no systemic disease, extending the known spectrum of MPS I and arguing for including IDUA in inherited retinal disease gene panels. The cohort is small and mostly of European ancestry, systemic assessment varied in depth, and without longitudinal follow-up some individuals classed as having isolated retinal disease may still develop systemic features. Article title: Hypomorphic IDUA genotypes are associated with retinitis pigmentosa in individuals without syndromic mucopolysaccharidosis type I First author: Lin Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.09.008 Reference: Lin, S., Yu, S.-H., Browning, A. C., et al., Roosing, S., Steet, R., and Arno, G. (2026). Hypomorphic IDUA genotypes are associated with retinitis pigmentosa in individuals without syndromic mucopolysaccharidosis type I. The American Journal of Human Genetics 113, 1-12. https://doi.org/10.1016/j.ajhg.2026.09.008 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/idua-hypomorphic-retinitis-pigmentosa-mps-i QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-11. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/out... Chapters (00:00:20) - Introduction: Two Faces of One Gene(00:01:54) - The Lysosome Crew Analogy(00:03:01) - Study Overview and Authors(00:03:44) - Understanding IDUA and MPS1(00:04:23) - MPS1 Severity Spectrum and Eye Involvement(00:05:41) - The Unclear Case of Retina-Only Disease(00:06:54) - Study Cohort and Methods(00:08:06) - Clinical Eye Workup and Testing(00:08:38) - Measuring Enzyme Activity in the Lab(00:09:44) - RNA Sequencing of a Puzzling Variant(00:10:18) - Genetic Findings: One Null, One Missense(00:10:49) - Clinical Results: Retina Affected, Body Spared(00:12:01) - Biochemical Results: Reduced but Not Absent(00:12:37) - Variant-by-Variant Activity Results(00:13:50) - The Recurrent Splicing Variant Mystery(00:14:26) - Long-Read Sequencing Reveals Leaky Splicing(00:15:37) - Why the Retina Fails First(00:16:15) - Clinical Implications for Diagnosis and Panels(00:16:51) - Therapeutic Implications(00:17:18) - Newborn Screening Dilemma(00:17:55) - Study Limitations(00:18:31) - Conclusions and Open Questions(00:19:31) - Closing and Credits
464: Burning fat while sparing muscle on GLP-1 drugs, in mice
2026/10/06
Thorne et al., Proceedings of the National Academy of Sciences - GLP-1 receptor agonists such as semaglutide produce large weight loss, but part of what is lost is lean mass, energy expenditure falls, and weight tends to return when treatment stops. This study tests a complementary idea in mice: switching on heat-producing fat by silencing ZFP423, a repressor of brown and beige fat identity, with an adipose-targeted antisense oligonucleotide. The RNA drug raised energy expenditure and improved metabolism on its own, and combined with semaglutide it produced more weight and fat loss while roughly halving the loss of lean mass. Key terms: GLP-1 receptor agonist, ZFP423, antisense oligonucleotide, adipose thermogenesis, lean mass. Study Highlights: Antisense oligonucleotides against Zfp423 were linked to palmitic acid to reach fat tissue, and two of twelve candidates, ASO37 and ASO44, were selected for strong knockdown without signs of toxicity. In lean mice on chow, weekly treatment for 10 weeks beiged white fat, raised oxygen consumption and body surface temperature without changing activity, and improved glucose tolerance even though body weight stayed the same, while muscle and heart function were preserved. In obese mice, three doses lowered fasting triglycerides, glucose and body weight, and fat mitochondria from treated mice showed more than threefold higher oxygen consumption than controls, partly through UCP1 and partly through the futile creatine cycle. Combined with semaglutide, ASO37 produced 9.2 g of weight loss against 6.6 g for either drug alone, cut body fat to 4.2 g, and limited lean mass loss to 5.5% compared with about 10% with semaglutide alone. Conclusion: In mice, silencing ZFP423 in fat with an RNA drug turns on thermogenic beige fat and complements GLP-1 receptor agonist treatment by adding fat loss and sparing lean mass. The work was done only in mice, the antisense drugs target mouse Zfp423 rather than human ZNF423, combination studies lasted three weeks, and several authors are employees of Ionis Pharmaceuticals or inventors on a related patent application. Article title: An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss First author: Thorne Journal: Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.2618845123 Reference: Thorne, A. K., Waldeck, N. J., Rose, J. P., Stachowski, M. J., Guak, H., Keeble, A. R., et al., and Bass, J. (2026). An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss. Proceedings of the National Academy of Sciences 123(40), e2618845123. https://doi.org/10.1073/pnas.2618845123 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/zfp423-rna-therapy-beige-fat-glp1-lean-mass QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-06. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/outro, and music - transcript coverage: Audited the ZFP423 rationale... Chapters (00:00:20) - Introduction: The Problem with Weight Loss Drugs(00:01:11) - GLP1 Drugs and Their Limitations(00:01:41) - A New Hypothesis: Burning Fat as Heat(00:02:12) - Study Overview and Publication(00:02:48) - Obesity, Fat Types, and Thermogenesis(00:04:00) - The Body Clock and ZFP423 Discovery(00:04:59) - Timing, Metabolism, and the Gene's Role(00:05:41) - Designing the Antisense Oligonucleotide Drug(00:06:47) - Single Cell Sequencing Methods(00:07:22) - Experimental Design Across Mouse Models(00:07:58) - Results in Lean Mice: Body Composition Shifts(00:08:29) - Organ and Hormone Effects(00:09:01) - Extra Eating but No Weight Gain: Energy as Heat(00:09:30) - Gene Expression Confirms Mechanism, Muscle Spared(00:10:02) - Testing in Obese Mice: Dose Response(00:10:33) - Heart Function Improvements(00:11:02) - Mitochondrial Mechanisms: Two Furnaces(00:12:08) - Single Cell Reorganization of Fat(00:12:45) - Combination Therapy: ASO Plus Semaglutide(00:13:19) - Preserving Muscle Mass and Function(00:14:21) - Energy Expenditure and Metabolic Outcomes(00:14:56) - Why This Matters for Obesity Treatment(00:15:26) - The Muscle Loss Concern Explained(00:15:56) - Study Limitations(00:16:31) - Conflicts of Interest Disclosure(00:16:59) - Conclusions and Future Outlook(00:17:48) - Closing and Credits
463: Why brain traits leave faint, common genetic signals
2026/10/04
Zhu et al., Proceedings of the National Academy of Sciences - Genome-wide studies of schizophrenia and other psychiatric disorders find hundreds of hits, yet those hits barely clear the significance threshold and tend to be common variants, unlike traits such as LDL cholesterol. This study shows that other traits whose heritability is enriched in the central nervous system share the same pattern, that the pattern survives careful matching of statistical power between binary and quantitative traits, and that it is best explained by an evolutionary model in which brain-related traits have very large mutational targets and their variants face stronger selection. Key terms: genetic architecture, natural selection, GWAS, psychiatric genetics, mutational target size. Study Highlights: Using stratified LD score regression across 220 cell types, the authors classified 164 traits and found 50 brain-related quantitative traits and four brain-related disorders, all psychiatric, among 151 UK Biobank traits and 13 diseases. Schizophrenia hits had a narrower spread of z-scores and higher minor allele frequencies than LDL or coronary artery disease hits, and the difference remained after downsampling the other GWAS to the effective sample size of the schizophrenia study. Fitting a pleiotropic stabilizing selection model, they inferred a selection distribution shifted toward stronger selection for brain-related traits and a median mutational target of about 1.32% of the genome, against 0.27% for other traits. Simulations showed that stronger selection, once GWAS ascertainment is applied, enriches hits for common variants, and rare loss-of-function burden tests showed that highly constrained genes have larger effects on brain-related traits than on other traits. Conclusion: Traits mediated by the central nervous system share a distinct genetic architecture of many small, relatively common effects, which the authors attribute to large mutational target sizes and stronger selection on brain-relevant variants and genes. The brain-related traits studied act as proxies for the processes under selection, so the specific targets of selection cannot be identified, and confounding was not fully excluded because family-based GWAS remain underpowered. Article title: Genetic architectures of brain-related traits are shaped by strong selective constraints First author: Zhu Journal: Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.2609814123 Reference: Zhu, H., Simons, Y. B., Spence, J. P., Sella, G., and Pritchard, J. K. (2026). Genetic architectures of brain-related traits are shaped by strong selective constraints. Proceedings of the National Academy of Sciences 123(36), e2609814123. https://doi.org/10.1073/pnas.2609814123 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/brain-traits-strong-selection-genetic-architecture QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-10-04. QC Scope: - article metadata and core scientific claims from the narration - excludes analog... Chapters (00:00:20) - Introduction: The Loud Room and the Whisper Room(00:01:20) - The Puzzle: Weak, Common Hits in Psychiatric Genetics(00:02:31) - Study Overview and Research Team(00:03:08) - What Is Genetic Architecture and Why It Matters(00:04:14) - The Stabilizing Selection Model(00:05:30) - Identifying Brain-Related Traits(00:06:51) - Comparing Diseases and Traits Fairly(00:07:59) - Modeling Selection and Mutational Target(00:08:38) - Key Findings: LDL vs Coronary Disease vs Schizophrenia(00:09:43) - The Pattern Across Psychiatric and Behavioral Traits(00:10:54) - Ruling Out Study Design as the Explanation(00:11:32) - Evolutionary Signatures: Stronger Selection, Larger Targets(00:12:41) - Why Stronger Selection Produces Common Hits(00:13:19) - Independent Evidence from Gene Constraint(00:14:22) - Explaining the History of Psychiatric Genetic Discovery(00:14:58) - Why the Brain May Face Stronger Selection(00:15:35) - Limitations and Caveats(00:16:44) - Conclusions and Broader Implications(00:17:48) - Closing and Credits
462: A vessel gene tied to AMD dims low-light vision in mice
2026/09/30
Cheng et al., Proceedings of the National Academy of Sciences - Genome-wide studies have found dozens of risk loci for age-related macular degeneration, but for many of them the gene doing the work is unknown. This study combines AMD genetics with blood and retinal gene-expression data to prioritize nine candidate genes, screens them in zebrafish, and follows the strongest, CNN2, into knockout mice. Mice lacking Cnn2 lose sensitivity in dim light and to fine contrast while acuity stays normal, and their photoreceptor layer thins, even though the gene is expressed mainly in the retina's blood-vessel cells rather than in photoreceptors. Key terms: age-related macular degeneration, CNN2, statistical genetics, photoreceptor degeneration, retinal neurovascular homeostasis. Study Highlights: Summary-data-based Mendelian randomization combining an AMD genome-wide study of 16,144 cases and 17,832 controls with blood expression data from 2,765 people found 16 genes, and the HEIDI test kept 9 whose signals were not explained by linkage, 4 of which replicated in retinal data from 406 donors. In zebrafish larvae, morpholino knockdown of cnn2 shrank eye area by 48.5% and axial length by 32.5%, cut the light-on visual motor response by 61.9%, and both defects were largely rescued by injecting cnn2 mRNA. Cnn2 knockout mice at 3 months had a 39.2% lower a-wave and a 27.3% lower b-wave in dim-light electroretinograms and needed 15.3% contrast to respond where wild-type mice needed 4.1%, while bright-light responses and visual acuity were unchanged. The photoreceptor layer thinned by 3 and 5 months, cone arrestin and rhodopsin fell, and the 436 genes altered in the retina were enriched 6.02-fold near known AMD risk loci. Cnn2 was expressed mainly in endothelial cells and pericytes, and in human retinas it was lower in AMD but not significantly so. Conclusion: Human genetic evidence and experiments in two species converge on CNN2, a calponin gene active mainly in retinal blood-vessel cells, as a candidate susceptibility gene for age-related macular degeneration. The authors propose that its loss disturbs neurovascular balance and harms photoreceptors secondarily, but the data do not yet show whether the effect is direct or indirect, and neither model has a macula. Music: Enjoy the music based on this article at the end of the episode. Article title: Genetic evidence and cross-species functional characterization implicate CNN2 in age-related macular degeneration susceptibility First author: Cheng Journal: Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.2533682123 Reference: Cheng, F.-F., Mou, H., Liu, Z., Zhang, C.-J., Zhuang, Y.-Y., Wu, Z., Wen, X.-R., Xue, A., Zhang, X., Yang, J., and Jin, Z.-B. (2026). Genetic evidence and cross-species functional characterization implicate CNN2 in age-related macular degeneration susceptibility. Proceedings of the National Academy of Sciences 123(36), e2533682123. https://doi.org/10.1073/pnas.2533682123 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cnn2-amd-vessel-gene-low-light-vision-mice QC: This... Chapters (00:00:10) - Intro and the dimming eye metaphor(00:00:57) - The retina stage: performers and crew(00:02:28) - Macular degeneration: overview and prevalence(00:04:19) - The genetic gap: regions vs genes(00:05:28) - Mendelian randomization narrows candidates(00:06:29) - Validating candidates across tissues(00:07:21) - Zebrafish screening of candidate genes(00:08:30) - Zebrafish results: CNN2 and SARM1 effects(00:09:38) - Focusing on CNN2 in mice(00:10:11) - Mouse vision tests: contrast and sensitivity(00:11:17) - Retinal structure changes in knockout mice(00:11:44) - Where CNN2 is expressed: vessels not photoreceptors(00:12:46) - What is CNN2 and proposed mechanism(00:13:14) - Caveats and limitations of the study(00:14:27) - Significance and future implications(00:15:05) - Summary and closing thoughts(00:16:08) - Credits and outro(00:16:49) - Original song: The dimming eye ballad

Podcast reviews

Read Base by Base podcast reviews


3 out of 5
2 reviews

Podcast sponsorship advertising

Start advertising on Base by Base relevant audience podcasts


What do you want to promote?